跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CNS-1
首页
药物
CNS-1
CNS-1
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
US 8134029 B2
申请人: JERUSSI THOMAS
优先权: 2010
US
12 件公开
Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US 2007082940 A1
申请人: SKOLNICK PHIL
优先权: 2005
CN
US
11 件公开
Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide
US 7087785 B2
申请人: SEPRACOR INC
优先权: 2003
US
11 件公开
CN 100584818 C
申请人: SEPRACOR INC
优先权: 2002
CN
SALTS OF A ISOCHROMANYL COMPOUND AND CRYSTALLINE FORMS, PROCESSES FOR PREPARING, THERAPEUTIC USES, AND PHARMACEUTICAL COMPOSITIONS THEREOF
EP 3938045 A1
申请人: SUNOVION PHARMACEUTICALS INC
优先权: 2019
CN
EP
US
WO
9 件公开
CRYSTALLINE FORMS OF A NEUROACTIVE STEROID
EP 4377327 A1
申请人: SAGE THERAPEUTICS INC
优先权: 2021
CN
EP
US
WO
9 件公开
US 20260242410 A1
申请人: SAGE THERAPEUTICS INC
优先权: 2022
US
WO
2 件公开
Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders
US 8071600 B2
申请人: YAMASHITA HIROSHI
优先权: 2005
CN
US
9 件公开
MOLECULAR TRANSPORT SYSTEM TO THE CENTRAL NERVOUS SYSTEM
EP 4121080 A1
申请人: STANFORD RES INST INT
优先权: 2020
CN
EP
US
WO
7 件公开
3-(Heteroaryl-Oxy)-2-Alkyl-1-Aza-Bicycloalkyl Derivatives As Alpha. 7-Nachrligands For TheTreatment Of Cns Diseases
US 2008194573 A1
申请人: NOVARTIS AG
优先权: 2004
CN
EP
US
6 件公开
Crystalline forms and processes for the preparation of cannabinoid receptor modulators
US 9458136 B2
申请人: BLACKBURN ANTHONY C
优先权: 2012
CN
US
6 件公开
PHENYL-3,4-DIHYDROISOQUINOLIN-2(1H)-YL-ETHAN-1-ONE DERIVATIVES AS DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
EP 4200280 A1
申请人: LILLY CO ELI
优先权: 2020
CN
EP
US
WO
5 件公开
第 1 / 10 页
上一页
下一页
药物
反馈